Male infertility. Male infertility
Conditions
Interventions
Intervention 1: Control group: Two tablets of 400 mg of pentoxifylline ( Manufactured by Hakim Pharmaceutical Company. Tehran-Iran) will be taken daily for three months each day. Intervention 2: Inte
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Willingness to cooperate Passing for at least one year from the time you decide to give birth and not use contraceptives Men aged 20-45 Concerning the decline in sperm motility with unknown cause based on WHO criteria (less than 50% sperm motility) Normal levels of gonadotropins, testosterone and serum prolactin
Exclusion criteria
Exclusion criteria: Infection of the genital system anatomical abnormalities in the genital system such as varicocele from the operation and not, cryptorchidism and ... systemic diseases or drug treatments in the last three months History of surgical procedures on the testes and vas deferens Patients with ICSI candidate due to severe spermogram disorder and presence of other infertility factors Contact with pesticides, heavy metals and solvents; use of antioxidant supplement in the last three months Coagulation disorders, infection, eczema at the site of needle and phobia from the needle
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sperm motility. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Spermogram.;Sperm count. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Spermogram.;Sperm morphology. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Spermogram.;Prolactin hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.;Testosterone hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.;Luteinizing hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.;Follicle stimulating hormone. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.;Malondialdehyde. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader.;C-Reactive Protein. Timepoint: Before the start of the study and three months after the start of the intervention. Method of measurement: Elisa Reader. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamidreza Bahrami Taghanaki
Mashhad University of Medical Sciences
Outcome results
None listed